- Home
- PLUR vs PTN Comparison
PLUR vs PTN Comparison
Compare PLUR & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- PTN
- Stock Information
- Founded
- PLUR 2001
- PTN 1986
- Country
- PLUR Israel
- PTN United States
- Employees
- PLUR N/A
- PTN N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- PTN Health Care
- Exchange
- PLUR Nasdaq
- PTN Nasdaq
- Market Cap
- PLUR 30.2M
- PTN 27.4M
- IPO Year
- PLUR N/A
- PTN 1993
- Fundamental
- Price
- PLUR $4.81
- PTN $1.02
- Analyst Decision
- PLUR
- PTN Strong Buy
- Analyst Count
- PLUR 0
- PTN 1
- Target Price
- PLUR N/A
- PTN $17.00
- AVG Volume (30 Days)
- PLUR 16.4K
- PTN 451.4K
- Earning Date
- PLUR 11-11-2024
- PTN 11-12-2024
- Dividend Yield
- PLUR N/A
- PTN N/A
- EPS Growth
- PLUR N/A
- PTN N/A
- EPS
- PLUR N/A
- PTN N/A
- Revenue
- PLUR $326,000.00
- PTN $4,490,090.00
- Revenue This Year
- PLUR N/A
- PTN N/A
- Revenue Next Year
- PLUR N/A
- PTN $2,382.84
- P/E Ratio
- PLUR N/A
- PTN N/A
- Revenue Growth
- PLUR 13.59
- PTN N/A
- 52 Week Low
- PLUR $3.44
- PTN $0.68
- 52 Week High
- PLUR $8.48
- PTN $5.65
- Technical
- Relative Strength Index (RSI)
- PLUR 42.15
- PTN 47.76
- Support Level
- PLUR $4.52
- PTN $0.83
- Resistance Level
- PLUR $5.34
- PTN $0.91
- Average True Range (ATR)
- PLUR 0.40
- PTN 0.08
- MACD
- PLUR -0.06
- PTN 0.03
- Stochastic Oscillator
- PLUR 17.40
- PTN 91.67
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.